The mechanism of action of praziquantel: can new drugs exploit similar mechanisms?

Charlotte Thomas, David Timson

Research output: Contribution to journalArticle

Abstract

Praziquantel (PZQ) is the drug of choice for treating infection with worms from the genus Schistosoma. The drug is effective, cheap and has few side-effects. However, despite its use in millions of patients for over 40 years its molecular mechanism of action remains elusive. Early studies demonstrated that PZQ disrupts calcium ion homeostasis in the worm and the current consensus is that it antagonises voltage-gated calcium channels. It is hypothesised that disruption of these channels results in uncontrolled calcium ion influx leading to uncontrolled muscle contraction and paralysis. However, other experimental studies have suggested a role for myosin regulatory light chains and adenosine uptake in the drug’s mechanism of action. Assuming voltage-gated calcium channels do represent the main molecular target of PZQ, the precise binding site for the drug remains to be identified. Unlike other commonly used anti-parasitic drugs, there are few definitive reports of resistance to PZQ in the literature. The lack of knowledge about PZQ’s molecular mechanism(s) undermines our ability to predict how resistance might arise and also hinder our attempts to develop alternative antischistosomal drugs which exploit the same target(s). Some PZQ derivatives have been identified which also kill or paralyse schistosomes in culture. However, none of these are in widespread clinical use. There is a pressing need for fundamental research into the molecular mechanism(s) of action of PZQ. Such research would enable new avenues for antischsistosomal drug discovery.
Original languageEnglish
JournalCurrent Medicinal Chemistry
Volume25
Issue number1
DOIs
Publication statusPublished - 26 Sep 2018

Fingerprint

Praziquantel
Pharmaceutical Preparations
Calcium Channels
Paralysis
Ions
Schistosoma
Calcium
Myosin Light Chains
Drug Discovery
Muscle Contraction
Research
Adenosine
Homeostasis
Binding Sites
Infection

Bibliographical note

The published manuscript is available at EurekaSelect via http://www.eurekaselect.com/165702/article

Keywords

  • praziquantel
  • schistosomiasis
  • voltage-gated calcium channels
  • neglected tropical disease
  • calcium signalling
  • drug mechanism.

Cite this

@article{d38f62e6285640b7b40a36cb807f2df8,
title = "The mechanism of action of praziquantel: can new drugs exploit similar mechanisms?",
abstract = "Praziquantel (PZQ) is the drug of choice for treating infection with worms from the genus Schistosoma. The drug is effective, cheap and has few side-effects. However, despite its use in millions of patients for over 40 years its molecular mechanism of action remains elusive. Early studies demonstrated that PZQ disrupts calcium ion homeostasis in the worm and the current consensus is that it antagonises voltage-gated calcium channels. It is hypothesised that disruption of these channels results in uncontrolled calcium ion influx leading to uncontrolled muscle contraction and paralysis. However, other experimental studies have suggested a role for myosin regulatory light chains and adenosine uptake in the drug’s mechanism of action. Assuming voltage-gated calcium channels do represent the main molecular target of PZQ, the precise binding site for the drug remains to be identified. Unlike other commonly used anti-parasitic drugs, there are few definitive reports of resistance to PZQ in the literature. The lack of knowledge about PZQ’s molecular mechanism(s) undermines our ability to predict how resistance might arise and also hinder our attempts to develop alternative antischistosomal drugs which exploit the same target(s). Some PZQ derivatives have been identified which also kill or paralyse schistosomes in culture. However, none of these are in widespread clinical use. There is a pressing need for fundamental research into the molecular mechanism(s) of action of PZQ. Such research would enable new avenues for antischsistosomal drug discovery.",
keywords = "praziquantel, schistosomiasis, voltage-gated calcium channels, neglected tropical disease, calcium signalling, drug mechanism.",
author = "Charlotte Thomas and David Timson",
note = "The published manuscript is available at EurekaSelect via http://www.eurekaselect.com/165702/article",
year = "2018",
month = "9",
day = "26",
doi = "10.2174/0929867325666180926145537",
language = "English",
volume = "25",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
number = "1",

}

The mechanism of action of praziquantel : can new drugs exploit similar mechanisms? / Thomas, Charlotte; Timson, David.

In: Current Medicinal Chemistry, Vol. 25, No. 1, 26.09.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The mechanism of action of praziquantel

T2 - can new drugs exploit similar mechanisms?

AU - Thomas, Charlotte

AU - Timson, David

N1 - The published manuscript is available at EurekaSelect via http://www.eurekaselect.com/165702/article

PY - 2018/9/26

Y1 - 2018/9/26

N2 - Praziquantel (PZQ) is the drug of choice for treating infection with worms from the genus Schistosoma. The drug is effective, cheap and has few side-effects. However, despite its use in millions of patients for over 40 years its molecular mechanism of action remains elusive. Early studies demonstrated that PZQ disrupts calcium ion homeostasis in the worm and the current consensus is that it antagonises voltage-gated calcium channels. It is hypothesised that disruption of these channels results in uncontrolled calcium ion influx leading to uncontrolled muscle contraction and paralysis. However, other experimental studies have suggested a role for myosin regulatory light chains and adenosine uptake in the drug’s mechanism of action. Assuming voltage-gated calcium channels do represent the main molecular target of PZQ, the precise binding site for the drug remains to be identified. Unlike other commonly used anti-parasitic drugs, there are few definitive reports of resistance to PZQ in the literature. The lack of knowledge about PZQ’s molecular mechanism(s) undermines our ability to predict how resistance might arise and also hinder our attempts to develop alternative antischistosomal drugs which exploit the same target(s). Some PZQ derivatives have been identified which also kill or paralyse schistosomes in culture. However, none of these are in widespread clinical use. There is a pressing need for fundamental research into the molecular mechanism(s) of action of PZQ. Such research would enable new avenues for antischsistosomal drug discovery.

AB - Praziquantel (PZQ) is the drug of choice for treating infection with worms from the genus Schistosoma. The drug is effective, cheap and has few side-effects. However, despite its use in millions of patients for over 40 years its molecular mechanism of action remains elusive. Early studies demonstrated that PZQ disrupts calcium ion homeostasis in the worm and the current consensus is that it antagonises voltage-gated calcium channels. It is hypothesised that disruption of these channels results in uncontrolled calcium ion influx leading to uncontrolled muscle contraction and paralysis. However, other experimental studies have suggested a role for myosin regulatory light chains and adenosine uptake in the drug’s mechanism of action. Assuming voltage-gated calcium channels do represent the main molecular target of PZQ, the precise binding site for the drug remains to be identified. Unlike other commonly used anti-parasitic drugs, there are few definitive reports of resistance to PZQ in the literature. The lack of knowledge about PZQ’s molecular mechanism(s) undermines our ability to predict how resistance might arise and also hinder our attempts to develop alternative antischistosomal drugs which exploit the same target(s). Some PZQ derivatives have been identified which also kill or paralyse schistosomes in culture. However, none of these are in widespread clinical use. There is a pressing need for fundamental research into the molecular mechanism(s) of action of PZQ. Such research would enable new avenues for antischsistosomal drug discovery.

KW - praziquantel

KW - schistosomiasis

KW - voltage-gated calcium channels

KW - neglected tropical disease

KW - calcium signalling

KW - drug mechanism.

U2 - 10.2174/0929867325666180926145537

DO - 10.2174/0929867325666180926145537

M3 - Article

VL - 25

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 1

ER -